{
  "id": "mhgap#risk_safety_86e0f253",
  "title_en": "General — Risk Safety",
  "title_vi": "General — Nguy cơ An toàn",
  "text_en": "in utero. 3.69) and minor (OR = 17.76; 95% CI: 1.60 to 633.30) Implementation considerations congenital malformation were reported in infants of women taking sodium valproate. y The choice of medicine is affected by a number of factors, including seizure semiology, comorbidities, y Phenobarbital, phenytoin and carbamazepine were availability, cost and side-effects. also associated with higher risks of major and minor congenital malformations. y Women and girls of childbearing potential who are prescribed sodium valproate should be y Topiramate was associated with higher risks of advised to use effective contraception without major congenital malformations with no information interruption, for the entire duration of treatment. on minor congenital malformations available. Further information on contraception is available y The risk of major congenital malformation was in the WHO fact sheet on family planning and not significantly higher in infants of women taking contraceptive methods (185). They must be provided lamotrigine (OR = 0.96; 95% CI: 0.72 to 1.25) or with information on pregnancy prevention and risks levetiracetam (OR = 0.72; 95% CI: 0.43 to 1.16). No associated with use of sodium valproate during information on minor congenital malformations is pregnancy, and referred for contraceptive advice available. if they are not using effective contraception. When y There were no data on the teratogenic effect of choosing the contraception method, individual lacosamide. circumstances should be evaluated in each case, y There were no high-quality studies identified on involving the woman in the discussion to guarantee the side-effects related to ASM exposure exclusively her engagement and compliance with the through breast-milk and the 2015 recommendation chosen measures. has been validated by the GDG. y If a woman taking sodium valproate is planning y Due to the high risk of teratogenic effect with to become pregnant, a person trained in the valproic acid, the GDG believed it was important management of epilepsy in pregnant women should to provide clear directions on the use of ASM consider alternative treatment options. Women in women and girls with epilepsy who are of should be informed of the need to consult their childbearing potential and therefore made a physician as soon as they are planning pregnancy strong recommendation despite the low certainty and to urgently consult their physician in case of evidence. of pregnancy. y Every effort should be made to switch from sodium Remarks valproate to appropriate alternative treatment y Major congenital malformations include prior to conception. If switching is not possible, the malformations present from birth with surgical, woman should receive further counselling regarding medical, functional or cosmetic importance the risks of sodium valproate for the unborn child to (cardiac malformations, cleft lip/palate, club foot, support her informed decision-making. hypospadias, inguinal hernia, and undescended testes in boys). Minor congenital malformations include any congenital malformation that did not qualify as major congenital malformation. 83",
  "gloss_vi": "In utero. 3.69) and minor (or = 17.76; 95% ci: 1.60 to 633.30) implementation considerations congenital malformation were reported in infants of women taking sodium valproate.",
  "source": "WHO mhGAP-IG 2023",
  "url": "https://www.who.int/",
  "lang": "en",
  "axes": {
    "type": [
      "clinical",
      "everyday"
    ],
    "condition": [
      "General"
    ],
    "clinical_section": [
      "risk_safety",
      "screening_cues",
      "referral",
      "psychoeducation",
      "management",
      "caregiver"
    ],
    "life_topics": [
      "relationships"
    ],
    "advice_section": [],
    "audience": [],
    "risk_band": "high"
  },
  "index_text": "General — Risk Safety General — Nguy cơ An toàn in utero. 3.69) and minor (OR = 17.76; 95% CI: 1.60 to 633.30) Implementation considerations congenital malformation were reported in infants of women taking sodium valproate. y The choice of medicine is affected by a number of factors, including seizure semiology, comorbidities, y Phenobarbital, phenytoin and carbamazepine were availability, cost and side-effects. also associated with higher risks of major and minor congenital malformations. y Women and girls of childbearing potential who are prescribed sodium valproate should be y Topiramate was associated with higher risks of advised to use effective contraception without major congenital malformations with no information interruption, for the entire duration of treatment. on minor congenital malformations available. Further information on contraception is available y The risk of major congenital malformation was in the WHO fact sheet on family planning and not significantly higher in infants of women taking contraceptive methods (185). They must be provided lamotrigine (OR = 0.96; 95% CI: 0.72 to 1.25) or with information on pregnancy prevention and risks levetiracetam (OR = 0.72; 95% CI: 0.43 to 1.16). No associated with use of sodium valproate during information on minor congenital malformations is pregnancy, and referred for contraceptive advice available. if they are not using effective contraception. When y There were no data on the teratogenic effect of choosing the contraception method, individual lacosamide. circumstances should be evaluated in each case, y There were no high-quality studies identified on involving the woman in the discussion to guarantee the side-effects related to ASM exposure exclusively her engagement and compliance with the through breast-milk and the 2015 recommendation chosen measures. has been validated by the GDG. y If a woman taking sodium valproate is planning y Due to the high risk of teratogenic effect with to become pregnant, a person trained in the valproic acid, the GDG believed it was important management of epilepsy in pregnant women should to provide clear directions on the use of ASM consider alternative treatment options. Women in women and girls with epilepsy who are of should be informed of the need to consult their childbearing potential and therefore made a physician as soon as they are planning pregnancy strong recommendation despite the low certainty and to urgently consult their physician in case of evidence. of pregnancy. y Every effort should be made to switch from sodium Remarks valproate to appropriate alternative treatment y Major congenital malformations include prior to conception. If switching is not possible, the malformations present from birth with surgical, woman should receive further counselling regarding medical, functional or cosmetic importance the risks of sodium valproate for the unborn child to (cardiac malformations, cleft lip/palate, club foot, support her informed decision-making. hypospadias, inguinal hernia, and undescended testes in boys). Minor congenital malformations include any congenital malformation that did not qualify as major congenital malformation. 83 In utero. 3.69) and minor (or = 17.76; 95% ci: 1.60 to 633.30) implementation considerations congenital malformation were reported in infants of women taking sodium valproate."
}